CD4+ T-cell responses to Epstein-Barr virus nuclear antigen EBNA1 in Chinese populations are highly focused on novel...

Area of Science:

• Immunology
• Virology
• Oncology

Background:

• Epstein-Barr virus nuclear antigen 1 (EBNA1) is uniformly expressed in nasopharyngeal carcinoma (NPC), making it a potential target for T-cell immunotherapy.
• Understanding EBNA1 epitopes, especially CD4+ epitopes presented by HLA alleles, is crucial for developing effective immunotherapies, particularly in high-risk populations like Chinese individuals.

Purpose of the Study:

• To investigate CD4+ T-cell responses to Epstein-Barr virus nuclear antigen 1 (EBNA1) in healthy Chinese donors.
• To identify specific EBNA1 epitopes recognized by CD4+ T-cells and presented by common HLA alleles in this population.

Main Methods:

• Analysis of CD4+ T-cell responses to EBNA1 in 78 healthy Chinese donors.
• Epitope mapping to identify specific immunogenic regions within EBNA1.
• Assessment of T-cell recognition of EBNA1-expressing target cells.

Main Results:

• CD4+ T-cell responses were predominantly focused on a limited number of epitopes in the C-terminal region of EBNA1.
• A significant finding was a DP5-restricted epitope recognized by nearly half of the donors tested.
• The identified T-cell responses were capable of recognizing EBNA1-expressing target cells presenting the DP5-restricted epitope.

Conclusions:

• The C-terminal region of EBNA1 contains key epitopes for CD4+ T-cell recognition in the Chinese population.
• A specific DP5-restricted EBNA1 epitope represents a highly immunogenic target with potential for T-cell-based immunotherapy against NPC.
• These findings provide a foundation for designing targeted immunotherapies for nasopharyngeal carcinoma, especially in at-risk ethnic groups.